Key Takeaways: The 68Ga Gallium Generator scan is a next-generation nuclear medicine imaging technology delivering unmatched precision in diagnosing neuroendocrine tumours, prostate cancer, FAPI-avid tumours, insulinomas, and gliomas. Neurad Diagnostics operates one of the few in-house 68Ga Gallium Generators in the region, ensuring daily availability of Dotanoc, PSMA, FAPI, Exendin, and Trivehexin scans. Early, accurate diagnosis translates directly into better treatment outcomes and longer survival.
What Is the 68Ga Gallium Generator Scan? A Complete Overview
The 68Ga Gallium Generator scan represents one of the most significant advances in diagnostic oncology over the past two decades. Unlike conventional imaging such as CT or MRI, which primarily reveal anatomical structure, a 68Ga PET/CT scan maps the biological behaviour of cells at the molecular level. It does this by combining a radioactive gallium-68 isotope with a disease-specific targeting molecule (called a radiopharmaceutical or radioligand), which travels through the bloodstream and preferentially accumulates in abnormal tissue. At Neurad Diagnostics, we operate an advanced in-house 68Ga Gallium Generator facility, producing fresh radiopharmaceuticals daily.
Once inside the patient, the 68Ga radiopharmaceutical emits positrons that are detected by a PET scanner, generating high-resolution, three-dimensional images of disease activity throughout the entire body — often in a single two-hour appointment. The result is a level of diagnostic sensitivity and specificity that was simply not achievable with older imaging technologies. This makes the 68Ga Gallium Generator scan indispensable across oncology, endocrinology, and neuro-oncology.
Why an In-House 68Ga Gallium Generator Changes Everything
Most diagnostic centres that offer 68Ga PET scans must import the radiopharmaceutical from an external cyclotron facility. This creates a logistical bottleneck: the short half-life of gallium-68 (approximately 68 minutes) means any delay in transport can significantly degrade the quality of the dose before it reaches the patient. An in-house generator eliminates this vulnerability entirely. At Neurad Diagnostics, our 68Ga Generator produces fresh gallium-68 on demand, ensuring maximum radiochemical purity and consistent scan quality every single day.
Additionally, our in-house capability allows us to offer the full breadth of 68Ga-labelled radiopharmaceuticals currently in clinical use: Dotanoc, PSMA, FAPI, Exendin, and Trivehexin. Each targets a distinct disease pathway, and having all five available in one location positions Neurad Diagnostics as a truly comprehensive nuclear medicine centre. For patients, this means less waiting and faster clinical decision-making. For physicians, it means same-day or next-day scan availability with minimal advance notice.
68Ga Dotanoc Scan: The Gold Standard for Neuroendocrine Tumour Imaging
What Does the 68Ga Gallium Generator Dotanoc Scan Detect?
68Ga Dotanoc (68Ga-DOTA-NOC) is a somatostatin receptor-targeting radioligand that has revolutionised the detection and staging of neuroendocrine tumours (NETs). NETs arise from specialised cells of the neuroendocrine system and can occur in the pancreas, small intestine, appendix, lungs, and multiple other sites. They are notoriously difficult to detect with conventional imaging because they are often small, multifocal, and biochemically active long before they become anatomically apparent.
68Ga Dotanoc binds with high affinity to somatostatin receptor subtypes 2, 3, and 5, which are overexpressed on the surface of most NETs. Multiple peer-reviewed studies, including landmark research published in the Journal of Nuclear Medicine (NCBI/PubMed), confirm detection rates exceeding 90% for well-differentiated NETs — far surpassing older octreotide scintigraphy. This makes the 68Ga Dotanoc scan the unambiguous first-line functional imaging tool for NET diagnosis and management.
Clinical Indications for 68Ga Dotanoc PET/CT
- Initial staging of histologically confirmed neuroendocrine tumours
- Detection of unknown primary in patients with suspected NET metastases
- Restaging after surgery, ablation, or chemotherapy
- Selection of patients for peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE
- Monitoring response to somatostatin analogues such as octreotide or lanreotide
- Evaluation of carcinoid tumours, phaeochromocytomas, paragangliomas, and medullary thyroid carcinoma
For referring oncologists and gastroenterologists, the 68Ga Dotanoc scan available at Neurad Diagnostics has become the preferred first-line functional imaging investigation for any patient with a confirmed or suspected NET diagnosis. Our results are reported by experienced nuclear medicine physicians with dedicated NET expertise, ensuring clinically actionable reports. [Insert Internal Link to NET Diagnostic Services Page]
68Ga PSMA Scan: Precision Imaging for Prostate Cancer
Understanding the 68Ga PSMA PET/CT Scan at Neurad Diagnostics
Prostate-Specific Membrane Antigen (PSMA) is a cell-surface protein massively overexpressed in prostate cancer cells, making it an ideal molecular target for both imaging and therapy. The 68Ga PSMA scan (68Ga-PSMA-11 or 68Ga-PSMA-617) exploits this property to produce PET/CT images of unparalleled clarity for prostate cancer staging, restaging, and therapy selection. Available daily at Neurad Diagnostics via our in-house 68Ga Gallium Generator, this scan has fundamentally changed how prostate cancer is managed.
The clinical impact of PSMA PET/CT has been transformative. In patients with biochemically recurrent prostate cancer (rising PSA after radical prostatectomy or radiotherapy), conventional CT and bone scans fail to detect disease in a substantial proportion of cases — particularly when PSA levels are low (less than 1 ng/mL). The ProPSMA trial published in The Lancet (PubMed) demonstrated that 68Ga PSMA PET/CT correctly upstaged or downstaged 27% of high-risk prostate cancer patients compared to conventional imaging, directly changing treatment management.
Who Should Have a 68Ga PSMA Scan?
- Men with newly diagnosed high-risk or very high-risk prostate cancer requiring accurate staging before definitive treatment
- Patients with biochemically recurrent prostate cancer and rising PSA after treatment
- Evaluation of metastatic castration-resistant prostate cancer (mCRPC) burden prior to 177Lu-PSMA therapy
- Assessment of oligometastatic disease amenable to stereotactic body radiation therapy (SBRT)
- Patients where conventional imaging is inconclusive or negative despite rising PSA
68Ga FAPI Scan: Imaging the Tumour Microenvironment
What Makes the 68Ga FAPI Scan Unique?
The 68Ga FAPI scan (Fibroblast Activation Protein Inhibitor PET/CT) is one of the most exciting recent developments in oncological imaging. Unlike FDG PET, which targets glucose metabolism, FAPI targets the tumour microenvironment — specifically, cancer-associated fibroblasts (CAFs) that express fibroblast activation protein (FAP). CAFs are abundant in the stroma of most solid tumours, making FAPI a broadly applicable pan-tumour imaging agent available through our 68Ga Gallium Generator.
The clinical advantages of FAPI over conventional FDG PET/CT are particularly pronounced in tumour types with notoriously low FDG avidity, including pancreatic ductal adenocarcinoma (PDAC), gastric cancer, colorectal cancer with peritoneal metastases, hepatocellular carcinoma, and cholangiocarcinoma. In these cancers, FAPI PET/CT consistently detects more disease sites with lower background noise, enabling more accurate staging and treatment planning. Research published in the Journal of Nuclear Medicine confirms these advantages across multiple tumour types.
Clinical Applications of 68Ga FAPI PET/CT
- Staging and restaging of pancreatic cancer, gastric cancer, and colorectal cancer
- Detection of peritoneal carcinomatosis in gynaecological and gastrointestinal malignancies
- Evaluation of hepatocellular carcinoma (HCC) and biliary tract cancers where FDG is unreliable
- Assessment of bone and soft tissue metastases in breast and lung cancer
- Pre-treatment mapping for FAP-targeted radionuclide therapy with 177Lu-FAPI or 90Y-FAPI
- Research and clinical trials involving tumour-stroma targeting therapies
68Ga Exendin Scan: Molecular Precision for Insulinoma Detection
The Role of the 68Ga Gallium Generator Exendin Scan in Insulinoma Localisation
68Ga Exendin-4 PET/CT targets GLP-1 receptors (glucagon-like peptide-1 receptors), which are massively overexpressed in benign insulinomas. Insulinoma is a rare but clinically important pancreatic tumour presenting with profound hypoglycaemia due to unregulated insulin secretion. Conventional imaging modalities such as CT, MRI, and endoscopic ultrasound detect only 70–80% of insulinomas. In contrast, 68Ga Exendin achieves detection rates of over 95%, as demonstrated in multiple European cohort studies — making it the most sensitive localisation technique available for this specific tumour type.
- Patients with biochemically confirmed endogenous hyperinsulinaemic hypoglycaemia and negative conventional imaging
- Pre-operative localisation of sporadic benign insulinoma before laparoscopic or robotic enucleation
- Patients with MEN-1 syndrome and multiple pancreatic lesions
- Cases of persistent or recurrent hypoglycaemia after previous pancreatic surgery
Neurad Diagnostics is one of the very few centres in India offering 68Ga Exendin scanning as part of a comprehensive endocrine tumour imaging programme. For endocrinologists and metabolic surgeons dealing with refractory hypoglycaemia cases, this 68Ga Gallium Generator scan can be genuinely life-changing for patients. [Insert External Link to GLP-1R Insulinoma Research on PubMed]
68Ga Trivehexin Scan: Advanced Imaging for Gliomas and Integrin-Positive Tumours
What Is 68Ga Trivehexin and How Does It Work?
68Ga Trivehexin targets integrin αvβ6 and αvβ3, which play critical roles in tumour invasion, angiogenesis, and metastasis. High integrin expression is particularly characteristic of high-grade gliomas, pancreatic cancer, head and neck squamous cell carcinoma, and certain breast cancer subtypes. For neuro-oncology specifically, 68Ga Trivehexin offers a compelling complement to conventional MRI — particularly in differentiating tumour recurrence from radiation necrosis, a critical clinical dilemma that directly determines treatment strategy.
Available through our in-house 68Ga Gallium Generator at Neurad Diagnostics, Trivehexin PET/CT provides active tumour biology data that significantly improves the accuracy of post-treatment glioma evaluation. Our neuro-oncology team uses Trivehexin data in conjunction with MRI spectroscopy and perfusion imaging for the most comprehensive tumour characterisation available anywhere in the region.
Clinical Indications for 68Ga Trivehexin Scan
- Glioma grading and delineation for surgical and radiotherapy planning
- Differentiation of true tumour progression vs radiation necrosis in post-treatment glioma patients
- Evaluation of angiogenesis and tumour vascularity in solid tumours
- Imaging of integrin-positive metastatic disease in head and neck cancer
- Patient selection for integrin-targeted therapies currently under clinical investigation
- Assessment of pancreatic cancer invasion and vascular involvement
Preparing for Your 68Ga Gallium Generator Scan: Patient Preparation Guidelines
Preparation requirements vary by the specific radiopharmaceutical being used, but the following general guidelines apply to all 68Ga Gallium Generator scans at Neurad Diagnostics. Our team provides personalised written instructions at the time of booking.
General Preparation for 68Ga Gallium Generator Scan
- Fasting: A 4–6 hour fast is required prior to most 68Ga injections. For 68Ga Exendin, special glucose management protocols apply under medical supervision.
- Hydration: Drink 500–750 mL of water in the two hours before your appointment unless otherwise instructed.
- Medications: Somatostatin analogues (octreotide, lanreotide) must be withheld prior to Dotanoc scans — your referring physician will advise on timing.
- Diabetic patients: Blood glucose management is important for optimal image quality. Our team will provide specific guidance.
- Clothing: Wear comfortable, loose-fitting clothing. Remove all metal jewellery before the scan.
- Duration: Allow 2–3 hours for the entire appointment, including check-in, injection, uptake period, and image acquisition.
The 68Ga Gallium Generator scan itself is painless. The radiopharmaceutical is administered via a simple intravenous injection, after which you rest quietly for approximately 60–90 minutes before entering the PET/CT scanner. Actual scanning time is typically 20–30 minutes. The radiation dose involved is low and comparable to or less than that of a standard diagnostic CT scan, posing no significant health risk.
Safety Profile of 68Ga Radiopharmaceuticals
All 68Ga-labelled radiopharmaceuticals used at Neurad Diagnostics are manufactured to GMP standards and carry strong clinical safety records from extensive international use. Gallium-68 has a short physical half-life of 68 minutes, meaning radiation exposure is brief and self-limiting — decaying to negligible levels within approximately 11 hours post-injection. Adverse reactions are rare and typically mild, including occasional transient nausea or minor injection-site discomfort.
Patients who are pregnant or breastfeeding should inform our team at the time of booking, as radiation exposure during pregnancy requires individual risk assessment. The overall risk-benefit profile of the 68Ga Gallium Generator scan is highly favourable when weighed against the clinical value of the diagnostic information obtained.
68Ga Gallium Generator Scan vs. FDG PET/CT: Choosing the Right Imaging
FDG (18F-fluorodeoxyglucose) images glucose metabolism and is an excellent general-purpose cancer imaging agent. However, FDG has significant limitations — many tumour types, particularly low-grade NETs, prostate cancer, and mucinous adenocarcinomas, show low or absent FDG uptake, making staging unreliable. The specialised 68Ga radiopharmaceuticals at Neurad Diagnostics fill these gaps by targeting specific biological markers, delivering superior results for the tumours they are designed to image.
- Dotanoc — for somatostatin receptor-positive NETs and carcinoids
- PSMA — for prostate cancer at any stage
- FAPI — for FDG-negative or low-FDG tumours and peritoneal disease
- Exendin — specifically for GLP-1R-positive insulinomas
- Trivehexin — for integrin-positive gliomas and selected solid tumours
In many complex cases, a combination of FDG and a 68Ga scan provides the most comprehensive oncological picture. Our nuclear medicine consultants are available to discuss the optimal imaging strategy for your specific patient via our dedicated physician referral line. [Insert Internal Link to Contact / Referral Page]
Frequently Asked Questions About 68Ga Gallium Generator Scans
How long does a 68Ga Gallium Generator scan take?
The entire appointment at Neurad Diagnostics typically takes 2 to 3 hours from check-in to completion. This includes registration, IV cannula insertion, radiopharmaceutical injection, an uptake waiting period of 60–90 minutes, and actual PET/CT scanning of approximately 20–30 minutes.
When will I receive my 68Ga scan results?
Our nuclear medicine physicians aim to provide preliminary reports on the same day of scanning, with full structured reports available within 24 hours. For urgent clinical cases, same-day reporting can be arranged in coordination with the referring clinician.
Is the 68Ga Gallium Generator scan covered by health insurance?
Insurance coverage for 68Ga PET/CT scans varies by policy and insurer. Many major health insurance providers now recognise these scans for approved clinical indications. Our billing team can assist with pre-authorisation documentation. [Insert Internal Link to Insurance / Billing Page]
Can I drive home after the scan?
Yes. The 68Ga radiopharmaceutical has no sedative or neurological effects, and there is no requirement for anyone to drive you to or from the appointment. The only exception is 68Ga Exendin scans in insulinoma patients, where hypoglycaemia precautions may require supervised transport.
Why Choose Neurad Diagnostics for Your 68Ga Gallium Generator Scan?
Choosing the right facility for a specialised nuclear medicine scan is a consequential decision. The quality of the radiopharmaceutical, the calibre of the scanner, and — most importantly — the expertise of the reporting physician all directly impact the diagnostic accuracy of the result. Neurad Diagnostics offers a combination of capabilities that is genuinely rare in the region: an in-house 68Ga Gallium Generator ensuring daily fresh-dose availability across all five radiopharmaceuticals, a state-of-the-art PET/CT scanner, and a specialist nuclear medicine reporting team with deep expertise in oncological and endocrine imaging.
Our integrated approach — combining nuclear medicine, radiology, and clinical oncology expertise — ensures that every 68Ga Gallium Generator scan report is not merely a set of images but a clinically actionable document that supports your treatment team in making the best possible decisions. For appointments, referrals, or clinical enquiries about our 68Ga scan services, please contact our team today. [Insert Internal Link to Contact Page] [Insert Internal Link to Appointment Booking Page]